Company Profile

DIVIS LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE2725.2058.95 (+2.21 % )
PREV CLOSE (Rs.) 2666.25
OPEN PRICE (Rs.) 2690.00
BID PRICE (QTY) 2723.35 (2 )
OFFER PRICE (QTY) 2724.00 (4 )
VOLUME 19299
TODAY'S LOW / HIGH (Rs.)2663.40 2738.05
52 WK LOW / HIGH (Rs.)1466.95 2730
NSE2724.40 56.65 (+2.12 % )
PREV CLOSE(Rs.) 2667.75
OPEN PRICE (Rs.) 2682.00
BID PRICE (QTY) 2724.40 (7 )
OFFER PRICE (QTY) 2725.00 (50 )
VOLUME 797139
TODAY'S LOW / HIGH(Rs.) 2662.70 2737.60
52 WK LOW / HIGH (Rs.)1466 2731

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.59
TTM EPS (Rs.) 51.71
P/E Ratio 52.64
Book Value (Rs.) 275.61
Face Value (Rs.) 2
MCap (Rs. in Mn) 722618.75
Price/Earning (TTM) 46.36
Price/Sales (TTM) 13.61
Price/Book (MRQ) 9.88
PAT Margin (%) 27.31
ROCE (%) 28.06
Incorporation Year : 1990

Management Info :

Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director

Registered Office :

Address : 1-72/23(p)/divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone : 040 2378 6300

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
15Jul07-15-2020$Divis Laboratories informs about certificate Divis Laboratories informs a

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, Divis Laboratories has informed that it has submitted a certificate from KFin Technologies (formerly known as Karvy Fintech), Registrar & Share Transfer Agent of the Company dated 09 July, 2020 for the quarter ended 30 June, 2020.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 74(5) of SEBI (Depositories and Particip..
09Mar03-09-2020$Divi’s Laboratories starts commercial production from DCV-SEZ Unit in Visakhapatnam Divi’s Laboratories starts

Divi’s Laboratories has commenced commercial production effective from March 09, 2020 from DCV-SEZ Unit of the company at Chippada Village, Bheemunipatnam Mandal, Visakhapatnam.

Divi’s Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates.

Divi’s Laboratories has commenced commercial production effec..
09Mar03-09-2020$Divis Laboratories informs about commencement of commercial production Divis Laboratories informs a

Divis Laboratories has informed that the Company has commenced commercial production effective from 09 March, 2020 from DCV-SEZ Unit of the Company at Chippada Village, Bheemunipatnam Manda), Visakhapatnam.

The above information is a part of company’s filings submitted to BSE.

Divis Laboratories has informed that the Company has commenced..
01Feb02-01-2020$USFDA completes inspection at Divi’s Laboratories’ Unit-II facility in Andhra Pradesh USFDA completes inspection a

US Food and Drug Administration (USFDA) has completed inspection at Divi’s Laboratories’ Unit-II, Village Chippada, Bheemunipatnam District in the state of Andhra Pradesh. The inspection was conducted from January 27 to 31, 2020. The inspection has been concluded with no ‘483’ observations.

Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

US Food and Drug Administration (USFDA) has completed inspectio..
20Jan01-20-2020$Divi' s Laboratories submits RTA certificate Divi' s Laboratories submits

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, Divi' s Laboratories has informed about submission of certificate from KFin Technologies (formerly known as Karvy Fintech), Registrar & Share Transfer Agent (RTA) of the Company dated 14 January, 2020 for the quarter ended 31 December, 2019. 

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 74(5) of SEBI (Depositories and Particip..
Financials More
Rs. in Millions
QTR Mar 20 ANNUAL 20
Net Profit391813727.1
Gross Profit 4752.2 18132.9
Operating Profit 5251.620053
Net Sales 13762.453105.7
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Aarti Drugs (BSE)
 2056.65 (9.25%)
M.Cap ( in Cr)
4745.86
Valiant Organics (BSE)
 2310.00 (6.70%)
M.Cap ( in Cr)
2782.17
Torrent Pharma (BSE)
 2929.20 (2.40%)
M.Cap ( in Cr)
49709.29
Piramal Enterprises (BSE)
 1480.25 (3.30%)
M.Cap ( in Cr)
33072.93
Caplin Point Lab (BSE)
 611.90 (6.72%)
M.Cap ( in Cr)
4567.31
Shareholding Pattern More
PROMOTERS 51.97 %
MUTUAL FUNDS/UTI 15.57 %
NON-INSTITUTION 13.07 %
FI/BANKS/INSURANCE 1.23 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes